Supernus Pharmaceuticals
Latest round
- Series A
Last raised
- Jan 2006
Total raised
- $49M
Investors
- 3
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc. was established in 2005 in Rockville, US, focusing on CNS treatments. The company underwent a strategic shift, divesting its subsidiary, TCD Royalty, for USD 27 mn in December 2011.Supernus Pharmaceuticals specializes in the development and commercialization of innovative treatments for central nervous system (CNS) diseases. Their core product offerings include a range of pharmaceuticals designed to address conditions such as attention-deficit hyperactivity disorder (ADHD) and epilepsy. Notable products in their portfolio include Qelbree™, which is specifically aimed at providing a non-stimulant treatment option for ADHD, and other therapies that focus on improving health outcomes for patients suffering from CNS disorders. Supernus actively targets healthcare providers, patients, and caregivers as its primary customer base, ensuring that its solutions meet the substantial health needs of individuals with CNS diseases.Supernus Pharmaceuticals generates revenue through sales of its prescription medications, with a focus on direct transactions with healthcare providers and pharmacies.90 mn. Pricing structures for their flagship products, such as Qelbree™, are determined based on market factors and competitive positioning, allowing the company to maintain a steady flow of revenue from their established product lines.Supernus Pharmaceuticals is focused on expanding its presence in the CNS treatment market by launching new products and entering additional geographical regions. The company aims to enhance its portfolio with upcoming offerings designed to address unmet medical needs in CNS diseases. Additionally, Supernus plans to explore new markets beyond North America, with specific strategies to be implemented by the end of 2024.
Who invested in Supernus Pharmaceuticals
3 investors across 1 round
See all investors in Supernus Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 12, 2006
Amount
$49M
Investors
Questions about Supernus Pharmaceuticals
Who invested in Supernus Pharmaceuticals?
Supernus Pharmaceuticals has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Supernus Pharmaceuticals raised?
Supernus Pharmaceuticals has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Supernus Pharmaceuticals last raise money?
Supernus Pharmaceuticals's most recent round on record is a Series A, in Jan 2006.
What does Supernus Pharmaceuticals do?
Supernus Pharmaceuticals is a pharmaceuticals company.
Where is Supernus Pharmaceuticals headquartered?
Supernus Pharmaceuticals is headquartered in Rockville, US.
Which VCs invest in companies like Supernus Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Supernus Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Supernus Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.